Effect of ursodeoxycholic acid therapy on hepatic function in children with intrahepatic cholestatic liver disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 26, Issue 1, 1998, Pages 49-55

  Narkewicz, Michael R ^a   Smith, Debra ^c   Gregory, Christopher ^b   Lear, James L ^a   Osberg, Iris ^b   Sokol, Ronald J ^c  

^a CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c NONE

Author keywords

Cholestasis; Cystic fibrosis; Galactose clearance; Ursodeoxycholic acid

Indexed keywords

ALANINE AMINOTRANSFERASE; URSODEOXYCHOLIC ACID;

ARTICLE; CHILD; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; INTRAHEPATIC CHOLESTASIS; JAUNDICE; LIVER DISEASE; LIVER FUNCTION; LIVER INJURY; LIVER SCINTISCANNING; MAJOR CLINICAL STUDY; MALABSORPTION; MALE; PRIORITY JOURNAL; PRURITUS;

ADOLESCENT; ADULT; ALANINE TRANSAMINASE; CAFFEINE; CHILD; CHILD, PRESCHOOL; CHOLESTASIS, INTRAHEPATIC; COPPER; CROSS-OVER STUDIES; GALACTOSE; GAMMA-GLUTAMYLTRANSFERASE; HALF-LIFE; HUMANS; LIVER; MANGANESE; TECHNETIUM TC 99M DISOFENIN; URSODEOXYCHOLIC ACID;

EID: 0031983394     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005176-199801000-00009     Document Type: Article

References (45)

1. Balistreri WF. Neonatal cholestasis. J Pediatr 1985;106:171-84.
2. Watson S, Giacoia GP. Cholestasis in infancy: A review. Clin Pediatr 1983;22:30-6.
3. Hoffenberg EJ, Narkewicz MR, Sondheimer JM, Smith DJ, Silverman A, Sokol RJ. Outcome of syndromic paucity of interlobular bile ducts (Alagille syndrome) with onset of cholestasis in infancy. J Pediatr 1995;127:220-4.
4. Whitington PF, Freese DK, Alonso EM, Schwarzenberg SJ, Sharp HL. Clinical and biochemical findings in progressive familial intrahepatic cholestasis. J Pediatr Gastroenterol Nutr 1994;18:134-41.
5. Sveger T. The natural history of liver disease in α1-antitrypsin deficient children. Acta Paediatr Scand 1988;77:847-51.
6. Clayton RJ, Iber F, Rucbner, BH, McKusick VA. Byler disease. Am J Dis Child 1969;117:112-24.
7. Nebbia G, Hadchouel M, Odievre M, Alagille D. Early assessment of evaluation of liver disease associated with alpha-1-antitrypsin deficiency in childhood. J Pediatr 1983;102:661-4.
8. Becker M, von Bergmann K, Rotthauwe HW, Leiss O. Biliary lipid metabolism in children with chronic intrahepatic cholestasis. Eur J Pediatr 1984;143:35-40.
9. Miyazaki K, Nakayama F, Koga A. Effect of chenodeoxycholic and ursodeoxycholic acids on isolated adult human hepatocytes. Dig Dis Sci 1984;29:1123-30.
10. Shaw BW, Wood RP, Kaufman SS, Williams L, Antonson DL, Vanderhoof J. Liver transplantation therapy for children: Part 1. J Pediatr Gastroenterol Nutr 1988;7:157-66.
11. Balistreri WF, A-Kader HH, Ryckman, FC, Whitington PF, Heubi JE, Setchell KD. Biochemical and clinical response to ursodeoxycholic acid administration in paediatric patients with chronic cholestasis. In: Paumgartner G. Stiehl A, Gerok W, eds. Bile acids as therapeutic agents. Lancaster, UK: Kluwer Academic Publishers. 1991:323-33.
12. Cotting J, Lentze MJ, Reichen J. Effects of ursodeoxycholic acid treatment on nutrition and liver function in patients with cystic fibrosis and longstanding cholestasis. Gut 1990;31:918-21.
13. Galabert C, Montet JC, Lengrand D, et al. Effects of ursodeoxycholic acid on liver function in patients with cystic fibrosis and chronic cholestasis. J Pediatr 1992;121:138-41.
14. Battezzati PM, Podda M, Bianchi FB, et al. Ursodeoxycholic acid for symptomatic primary biliary cirrhosis. J Hepatol 1993;17:332-8.
15. Heathcote EJ, Cauch-Dudeck K, Walker V, et al. The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994;19:1149-56.
16. Poupon RE, Poupon R, Balkau B. Group U-PS. Ursodiol for the long-term treatment of primary biliary cirrhosis. N Engl J Med 1994;330:1342-7.
17. Colombo C, Castellani MR, Balistreri WF, Seregni E, Assaisso ML, Giunta A. Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease. Hepatology 1992;15:681-4.
18. Colombo C, Battezzati PM, Podda M, Bettinardi N, Giunta A. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: A double-blind multicenter trial. Hepatology 1996;23:1484-90.
19. Colombo C, Crosignani A, Assaisso ML, et al. Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: A dose-response study. Hepatology 1992;16:924-30.
20. Whitington PF, Whitington GL. Partial external diversion of bile for the treatment of intractable pruritus associated with intrahepatic cholestasis. Gastroenterology 1988;95:130-6.
21. Harrison GG, Buskirk ER, Carter JEL, et al., Skinfold thicknesses and measurement technique. In: Lohman TG, Roche AF, Martorell R, eds. Anthropometric standardization reference manual. Champaign, IL: Human Kinetics Books, 1988:55-8.
22. Everson M, Warren B. Determination of serum copper by atomic absorption, with the use of the graphite cuvette. Clin Chem 1975;21:619-25.
23. Casey C, Jacobs M, Hambidge K. Atomic absorption spectrophotometry of manganese in plasma. Clin Chem 1987;33:1253-4.
24. Bieri JG, Tolliver TJ, Catignani GL. Simultaneous determination of alpha tocopherol and retinol in plasma or red cells by high pressure liquid chromatography. Am J Clin Nutr 1979;32:2143-9.
25. Belsey RE, DeLuca HF, Potts JT. A rapid assay for 25-OH-vitamin D3 without preparative chromatography. J din Endocrinol Metab 1974;38:1046-51.
26. Mancini G, Carbonara AO, Heremans JF. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry 1965;2:235-54.
27. Zoellner N, Kirsch K. A micromethod for lipids using a sulphooxanillin reaction. Z Gesamte Exp Med 1962;135:545-61.
28. Mourey MS, Siegenthaler G, Amedee-Manesme O. Regulation of metabolism of retinol-binding protein by vitamin A status in children with biliary atresia. Am J Clin Nutr 1990;51:638-43.
29. Horwitt MK, Harvey CC, Dahm CH. Relationship between tocopherol and serum lipid levels for determination of nutritional adequacy. Ann N Y Acad Sci 1972;203:223-36.
30. Schirmer WJ, Townsend MC, Schirmer JM, Hampton WW, Fry DE. Galactose clearance as an estimate of effective hepatic blood flow: Validation and limitations. J Surg Res 1986;41:543-56.
31. Rabe C, Whitington PF, Xenobiotic-based quantitative liver function tests. In: Suchy F, ed. Liver disease in children. St. Louis, MO: Mosby-Yearbook, 1994:283-93.
32. Hjelm M, de Verdier CH. Galactose: Colorimetric method with galactose oxidase. In: Bergmeyer H, Bergmeyer J, Grabl M. Methods of Enzymatic Analysis. 3rd ed. Vol. 6. Deerfield Beach, FL: Verlag Chemie, 1984:281-8.
33. Holstege A, Kurz M, Weinbeck M, Gerok W. Excretion of caffeine and its primary degradation products into bile. J Hepatol 1993;17:67-73.
34. Brody DH, Leichter L. Clearance tests of liver function. Med Clin North Am 1979;63:621-30.
35. Oellerich M. Enzyme immunoassays in clinical chemistry: Present status and trends. J Clin Chem Clin Biochem 1980;18:197-208.
36. Nakagawa M, Colombo C, Setchell KDR. Comprehensive study of the biliary bile acid composition of patients with cystic fibrosis and associated liver disease before and after UDCA administration. Hepatoloay 1990;12:322-34.
37. Steihl A, Walker S, Steihl L, Rudolph G, Hofmann WJ, Theilmann L. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A three-year study with a placebo-controlled study period. J Hepatol 1994;20:57-64.
38. Colombo C, Battezzati PM, Podda M. Hepatobiliary disease in cystic fibrosis. Semin Liver Dis 1994;14:259-69.
39. Ranek L, Buch Andreasen P, Tygstrup N. Galactose elimination capacity as a prognostic index in patients with fulminant liver failure. Gut 1976;17:959-64.
40. Reichen J, Widmer T, Cotting J. Accurate prediction of death by serial determination of galactose elimination capacity in primary biliary cirrhosis: A comparison with the Mayo model. Hepatology 1991;14:504-10.
41. Lindskov J. The quantitative liver function as measured by the galactose elimination capacity. I. Diagnostic value and relations to clinical, biochemical, and histological findings in patients with steatosis and patients with cirrhosis. Acta Med Scand 1982;212:295-302.
42. Salerno F, Borroni G, Moser P, et al. Prognostic value of the galactose test in predicting survival of patients with cirrhosis evaluated for liver transplantation. J Hepatol 1996;25:474-80.
43. Scott NR, Stambuk D, Chakraborty J, Marks V, Morgan MY. Caffeine clearance and bio-transformation in patients with chronic liver disease. Clin Sci 1988;74:377-84.
44. Occena Ramirez R, Sokol RJ. Medical management of cholestasis. In: Suchy FJ, ed. Liver disease in children. St. Louis, MO: Mosby-Yearbook, 1994:356-388.
45. Bayliss EA, Hambidge KM, Sokol RJ, Stewart B, Lilly JR. Hepatic concentrations of zinc, copper and manganese in infants with extrahepatic biliary atresia. J Trace Elem Med Biol 1995;9:40-3.